Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/BioNTech to present promising late-stage cancer drug data at 2026 ASCO meeting

BNTX

$91.90

-$0.09 -0.10%

BioNTech to present promising late-stage cancer drug data at 2026 ASCO meeting

Market News

22 May 2026

Biontech Se

View Source

Bullish

BioNTech will showcase new clinical data for its late-stage oncology drugs pumitamig and gotistobart at the 2026 ASCO Annual Meeting. Pumitamig showed encouraging anti-tumor activity in first-line non-small cell lung cancer, while gotistobart demonstrated durable effects in platinum-resistant ovarian cancer. The company is advancing over 25 Phase 2 and 3 trials, aiming to deliver innovative cancer treatments through monotherapies and novel combinations. These presentations highlight BioNTech's commitment to developing diverse therapies addressing high unmet medical needs in cancer.

More News (BNTX)

Head and neck squamous cell carcinoma market to grow 10.5% CAGR through 2036 with new immunotherapies.

The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a 10.5% CAGR from 2026 to 2036, driven by rising cancer incidence and new immunotherapy launches. Key emerging therapies from companies like Johnson & Johnson, BioNTech,...

Market News

Bullish

2 days ago